文献速递间质性肺疾病肺栓塞与肺血管病

JAK2介导特发性肺纤维化中的肺纤维化、肺血管重塑与肺动脉高压

JAK2 mediates lung fibrosis, pulmonary vascular remodelling and hypertension in idiopathic pulmonary fibrosis: an experimental study.
PubMed 文献 · Thorax · 2018-02-10

该实验研究探讨JAK2在特发性肺纤维化(IPF)相关肺动脉高压(PH)中的作用。IPF和IPF+PH患者肺动脉中JAK2表达分别升高1.93倍(P=0.0011)和2.65倍(P<0.0001)。抑制JAK2可减少内皮间质转化、平滑肌增殖并舒张肺动脉,在大鼠中减轻博来霉素诱导的纤维化和PH。

要点

  • IPF和IPF+PH患者肺动脉JAK2表达显著升高。
  • JAK2抑制在体外抑制内皮间质转化和平滑肌增殖。
  • JAK2抑制在大鼠中减轻肺纤维化、血管重塑和PH。

核心结论

  • JAK2参与肺动脉重塑和张力调节,可能是治疗IPF相关PH的潜在靶点。

研究设计与样本

  • 实验研究,比较IPF(n=10)、IPF+PH(n=9)和对照(n=10)的肺动脉JAK2表达。
  • 体外使用人肺动脉内皮细胞和平滑肌细胞,给予JAK2抑制剂JSI-124或siRNA-JAK2。
  • 大鼠博来霉素模型中给予JSI-124 1 mg/kg/day,评估纤维化、血管重塑和血流动力学。

主要发现

  • IPF患者肺动脉JAK2表达为对照的1.93倍(P=0.0011),IPF+PH为2.65倍(P<0.0001)。
  • JSI-124和siRNA-JAK2抑制TGF-β诱导的内皮间质转化和平滑肌向肌成纤维细胞转化及增殖。
  • JAK2抑制诱导小肺动脉舒张,依赖BKCa通道激活和细胞内Ca2+减少。
  • JSI-124 1 mg/kg/day减轻博来霉素诱导的肺纤维化、肺动脉重塑、右心室肥厚、肺动脉高压和V/Q失调。

临床怎么用

  • JAK2可能作为IPF相关PH的潜在治疗靶点,但尚未进入临床推荐。

局限性

  • 研究为实验性研究,样本量小,临床转化需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary hypertension (PH) is a common disorder in patients with idiopathic pulmonary fibrosis (IPF) and portends a poor prognosis. Recent studies using vasodilators approved for PH have failed in improving IPF mainly due to ventilation (V)/perfusion (Q) mismatching and oxygen desaturation. Janus kinase type 2 (JAK2) is a non-receptor tyrosine kinase activated by a broad spectrum of profibrotic and vasoactive mediators, but its role in PH associated to PH is unknown. OBJECTIVE: The study of JAK2 as potential target to treat PH in IPF. METHODS AND RESULTS: JAK2 expression was increased in pulmonary arteries (PAs) from IPF (n=10; 1.93-fold; P=0.0011) and IPF+PH (n=9; 2.65-fold; P<0.0001) compared with PA from control subjects (n=10). PA remodelling was evaluated in human pulmonary artery endothelial cells (HPAECs) and human pulmonary artery smooth muscle cells (HPASMCs) from patients with IPF in vitro treated with the JAK2 inhibitor JSI-124 or siRNA-JAK2 and stimulated with transforming growth factor beta. Both JSI-124 and siRNA-JAK2 inhibited the HPAEC to mesenchymal transition and the HPASMCs to myofibroblast transition and proliferation. JAK2 inhibition induced small PA relaxation in precision-cut lung slice experiments. PA relaxation was dependent of the large conductance calcium-activated potassium channel (BKCa). JAK2 inhibition activated BKCa channels and reduced intracellular Ca2+. JSI-124 1 mg/kg/day, reduced bleomycin-induced lung fibrosis, PA remodelling, right ventricular hypertrophy, PA hypertension and V/Q mismatching in rats. The animal studies followed the ARRIVE guidelines. CONCLUSIONS: JAK2 participates in PA remodelling and tension and may be an attractive target to treat IPF associated to PH.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Milara J, Ballester B, Morell A, et al. JAK2 mediates lung fibrosis, pulmonary vascular remodelling and hypertension in idiopathic pulmonary fibrosis: an experimental study. Thorax. 2018. PMID: 29440315. doi:10.1136/thoraxjnl-2017-210728

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。